Retired Professor
Contributor's Links: Shareholders Unite

We at Shareholders Unite are retired university professors from Amsterdam writing with a focus on small-cap, macro, value, and momentum.

Our analysis can be read on both TalkMarkets and more

ALL CONTRIBUTIONS

S Protalix PRX-102: Likely Approval Could Be A Game Changer
Protalix's PRX-102 drug stands a good chance of being accepted against Fabry disease, with three P3 trials delivering good results.
Read
S Ituran Is Set To Recover
The company was buffeted by the pandemic, a dividend cut, a car market growth decline, and negative currency effects but all of these seem to be disappearing.
Read
S Orgenesis' Leveraged Approach To Lower The Cost Of Cell And Gene Therapies
Orgenesis is an innovative biotech company in the CGT (Cell & Gene Therapy) space.
Read
S Medigus Is Facing Multiple Opportunities But Is Not Without Risk
While the company doesn't yet produce much in the way of revenues, it has stakes in multiple interesting opportunities and cash to last for quite a while. This is a high-risk, high-reward type of investment.
Read
S Medigus, A High-Risk, High-Reward Micro-Camera Play
Medigus, is a company producing the highly innovative micro-camera and sensors ScoutCam, orders for which are taking off this year. The company which also produces the MUSE system for GERD treatment, a business which they intent to sell.
Read
S Nxt-ID Gets A New Lease On Life
Nxt-ID has some promising businesses that are now about to be split with investors receiving shares of their finance business in a tax free distribution. What are the prospects?
Read

Comments

Latest Comments
Ituran Is Set To Recover
1 year ago

Yes, I was actually surprised how modestly priced the stock is, to be honest. Management is innovative and these applications tend to be quite sticky.

In this article: ITRN
Ituran Is Set To Recover
1 year ago

My pleasure Dick, appreciated.

In this article: ITRN
Ituran Is Set To Recover
1 year ago

There quite a few in the telematics space, they are mentioned in the 20-F, a few I covered are INSG and MiX Telematics. The market is growing and there Is quite a bit of segmentation in the market (by application, geography, technology, etc.) so it's not hypercompetitive.

In this article: ITRN
Orgenesis' Leveraged Approach To Lower The Cost Of Cell And Gene Therapies
1 year ago

Well, anything in the cell & gene therapy space, in theory, but it really depends on the therapy in question, and even that might not be a problem because Orgenesis argues they are doing things cheaper.

In this article: ORGS
Orgenesis' Leveraged Approach To Lower The Cost Of Cell And Gene Therapies
1 year ago

My pleasure Alexa. It's a pretty complex company, perhaps it's more like a little network, as it happens.

In this article: ORGS
Medigus Is Facing Multiple Opportunities But Is Not Without Risk
1 year ago

Yes, it's like a mini-conglomerate

In this article: MDGS, SCTC
Medigus Is Facing Multiple Opportunities But Is Not Without Risk
1 year ago

Yep, that's possible Adam, it's interesting tech which does good in medical appliances, but as with much tech, in the wrong hands it can do damage..

In this article: MDGS, SCTC
Medigus, A High-Risk, High-Reward Micro-Camera Play
2 years ago

Yep, they have some interesting technology which is applicable in numerous situations.

In this article: MDGS, SCTC
Nxt-ID Gets A New Lease On Life
2 years ago

Will let you know what they answered ASAP.

In this article: NXTD
Nxt-ID Gets A New Lease On Life
2 years ago

I'm not sure what the hold-up is, as puzzled as the commentators but I've contacted the company, stay tuned..

In this article: NXTD
1 to 10 of 17 comments
1 2

STOCKS I FOLLOW

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications